RAB20 and acute lymphoblastic leukemia: Pharmacological inhibition of CK2 using its specific inhibitor, CX-4945, as well as with a structurally-different CK2 inhibitor, TBB, also resulted in a strong negative effect on RAB20 transcription in both B-ALL cell lines (Figure 4D).